At Vesper we believe that a dedicated focus on a few, well selected, high potential companies is more effective than betting on a high number of cases with little dedication to each of them.
So far, we have managed to back several success stories.
Vesper has transitioned towards a biotech focused venture builder since 2016.
Aptah Biosciences SA
Through Aptah's technology we are able to modulate the spliceosome machinery and thus, the pre-mRNA, which ensures the precise control of the transcription step and modulation of specific gene expression -not only silencing, but also editing the pre-mRNA by hacking the spliceosome machinery.
Founded in 2019 by Caio Bruno & Higor Falcão.
Early Stage - Seed